This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
RXDX Overzicht aandelen
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD).
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Prometheus Biosciences, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$199.92 |
| 52 Week Hoogtepunt | US$199.98 |
| 52 Week Laag | US$25.65 |
| Bèta | -0.49 |
| 11 maand verandering | 3.51% |
| 3 maanden verandering | 77.52% |
| 1 Jaar Verandering | 684.31% |
| 33 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 690.51% |
Recent nieuws en updates
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Rendement voor aandeelhouders
| RXDX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.5% | -1.6% | -0.7% |
| 1Y | 684.3% | 17.6% | 32.5% |
Rendement versus industrie: RXDX exceeded the US Biotechs industry which returned 20.6% over the past year.
Rendement versus markt: RXDX exceeded the US Market which returned 17.7% over the past year.
Prijsvolatiliteit
| RXDX volatility | |
|---|---|
| RXDX Average Weekly Movement | 20.0% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: RXDX's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: RXDX's weekly volatility has decreased from 26% to 20% over the past year, but is still higher than 75% of US stocks.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2016 | 97 | Mark McKenna | www.prometheusbiosciences.com |
Prometheus Biosciences, Inc. Samenvatting
| RXDX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$9.56b |
| Inkomsten(TTM) | -US$150.56m |
| Inkomsten(TTM) | US$4.00m |
2,393x
P/S-verhouding-63.5x
Koers/WinstverhoudingIs RXDX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| RXDX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$4.00m |
| Kosten van inkomsten | US$121.34m |
| Brutowinst | -US$117.34m |
| Overige uitgaven | US$33.22m |
| Inkomsten | -US$150.56m |
Laatst gerapporteerde inkomsten
Mar 31, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.15 |
| Brutomarge | -2,937.17% |
| Nettowinstmarge | -3,768.76% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde RXDX op de lange termijn?
Bekijk historische prestaties en vergelijking